Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

HAT Platform


Founded: 2005 in Kinshasa, Democratic Republic of the Congo

The HAT platform builds and strengthens treatment methodologies and clinical trial capacity in sleeping sickness-endemic countries, so that new treatments for this fatal disease can be rapidly and effectively evaluated, registered, and made available to patients. After the success of the Nifurtimox-Eflornithine Combination Therapy (NECT), included in the WHO List of Essential Medicines for the treatment of stage 2 HAT, the primary goals of the HAT Platform are to develop appropriate clinical trial methodologies for sleeping sickness, overcome system challenges related to administrative and regulatory requirements, strengthen clinical trial capacity (human resources, infrastructure, equipment), and share information and strengthen ties among endemic countries.


HAT Platform Brochure

In the Media

[17 September, 2014]
Radio Okapi
"Dr Augustin Kadima Ebeja : 'La RDC est le pays le plus endémique
de la maladie du sommeil'"

Dr Augustin Kadima Ebeja en ‘Invité du Jour’ sur Radio Okapi (interview audio)
Click here to read the article

[17 September, 2014]
Radio Okapi
"Les moyens manquent"
Interview de Dr Augustin Kadima Ebeja
Click here to read the article

HAT Platform Newsletters

DNDi Newsletters


Tags: HAT – Sleeping Sickness
Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License